Study of a new medicine for hidradenitis suppurativa
Treatments studied
Part of Infections, Skin clinical trials.
This trial tests an investigational medicine, SPY072, for adults with moderate to severe hidradenitis suppurativa (also known as HS), a skin condition that causes painful lumps and sores. If you join, you'll help see if this treatment is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have had hidradenitis suppurativa symptoms for at least 6 months.
- You have symptoms in at least 2 different body areas, with at least one area being moderate or severe (Hurley stage II or III).
- You have at least 5 active boils or painful bumps (abscesses or inflammatory nodules).
- You have tried at least one systemic (body-wide) treatment for HS that did not work, caused side effects, or you couldn't take it.
- You do not have more than 20 draining tunnels (tracts under the skin that leak fluid).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medication called CIT-013 for people with moderate to severe hidradenitis suppurativa (HS) who have not had enough relief from oral antibiotics. The goal is to see if this treatment can reduce painful bumps and abscesses.
This trial tests a new medicine called SCT650C for people with moderate to severe hidradenitis suppurativa (HS). The goal is to see if it can reduce painful bumps and abscesses better than current treatments.
This trial is testing an experimental tablet called LT-002-158 in adults with moderate to severe hidradenitis suppurativa (HS) that hasn't improved enough with standard treatments. The goal is to see if it's safe and helps reduce painful lumps and abscesses.
This trial looks at a type of immune cell (MAIT cells) in people with hidradenitis suppurativa (a skin condition causing painful bumps). It aims to understand how these cells work and how they relate to treatments like adalimumab, secukinumab, or bimekizumab. You may be able to join if you have moderate-to-severe HS and are about to start one of these treatments.
This study tests a drug called secukinumab (a type of biologic that targets inflammation) for people with moderate to severe hidradenitis suppurativa (HS). It may be an option if you have tried other treatments and they didn't work well.
This trial tests a new medication, BFB759, to see if it can help people with moderate to severe hidradenitis suppurativa (a skin condition that causes painful bumps and abscesses) when antibiotics haven't worked well enough. It is designed for adults whose symptoms are not well controlled with current treatments.
Hear when a new Hidradenitis Suppurativa (HS) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.